- MDxHealth SA (OTCPK:MXDHF) announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) has issued a draft local coverage determination (LCD) for the SelectMDx for Prostate Cancer test.
- The draft LCD recommends coverage of the test for qualified Medicare patients throughout the U.S.
- SelectMDx for Prostate Cancer is a urine-based, molecular diagnostic test that offers a non-invasive liquid biopsy method to assess a patient's risk for prostate cancer.